Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Abvc Biopharma (ABVC) Finished Goods (2018 - 2019)

Historic Finished Goods for Abvc Biopharma (ABVC) over the last 2 years, with Q4 2019 value amounting to $94727.0.

Abvc Biopharma's Finished Goods fell 596.51% to $94727.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $94727.0, marking a year-over-year decrease of 596.51%. This contributed to the annual value of $94727.0 for FY2019, which is 596.51% down from last year.
Latest data reveals that Abvc Biopharma reported Finished Goods of $94727.0 as of Q4 2019, which was down 596.51% from $91341.0 recorded in Q3 2019.
Abvc Biopharma's 5-year Finished Goods high stood at $100736.0 for Q4 2018, and its period low was $91324.0 during Q2 2019.